• Login/Register
  • Contact Us
  • Advertise
FacebookLinkedInTwitterRSS Feeds

This Week in Print

View the E-Edition

Subscribe FREE Trial Offer

advertisement
  • Home
  • News
    • NJBIZ Daily
    • Grapevine
    • This Week's Issue
      • Top News
      • Spotlight
      • Opinion
      • Digital Edition
    • By Industry
      • Banking, Finance & Accounting
      • Energy & Utilities
      • Government
      • Health Care
      • Law
      • Manufacturing
      • Pharma & Life Sciences
      • Real Estate
      • Retail
      • Sports & Entertainment
      • Technology
      • Transportation
    • Regional News
      • North Jersey
      • Central Jersey
      • South Jersey
    • Morning Roundup
    • National / International News
  • Events
    • Event Calendar
    • Post an Event
  • Lists
  • Special Editions
  • Subscribe
Site sponsored by:

advertisement
 
STOCK SUMMARY
Nasdaq 2847.78-2.34
S&P 500 1321.31+2.45
Automatic 53.31+0.47
Bed Bath & 72.00+0.99
Campbell S 32.55+0.13
Hertz 13.12+0.03
Honeywell 57.30-0.32
Johnson & Johnson 63.27+0.61
Merck & Co "37.60
NRG Energy Inc. "15.75
Public Ser 30.78+0.08
Chubb Corp 71.78+0.12
 
Thursday
Thursday
High 80 °F
Low 64 °F
72 °F
Mostly Cloudy with Haze

February 21. 2012 5:20PM

J&J announces retirement of CEO

By Jared Kaltwasser

Alex Gorsky


Johnson & Johnson CEO William C. Weldon will step down in April, the company announced Tuesday afternoon.


Alex Gorsky, who has been vice chairman of the company's executive committee for the past year, will take over as CEO and join the company's board of directors, though Weldon will keep his title of chairman.

The transition is timed to the company's annual shareholder meeting, which takes place April 26.

Weldon, 63, joined J&J in 1971, and has been its CEO since 2002. He hands the reins to Gorsky at a time of great challenge for the health care giant, which has been beset by numerous product recalls dating back to 2009. Most of the recalls were traced to manufacturing problems at the company's McNeil Consumer Healthcare unit.

"I'm honored that the board has placed such confidence in me, and I am also aware of the serious responsibilities that come with this office," Gorsky said in a written statement. "Johnson & Johnson is a strong and extraordinary company with enormous opportunities to advance health and well being."

Gorsky, 51, joined the company as a sales representative in 1988. In 2004, he left for Novartis Pharmaceuticals, and rejoined J&J in 2008, and has been in charge of J&J's medical device and diagnostics businesses. Sheri S. McCoy, who was elevated to vice chairman last year along with Gorsky, will continue to lead the company's pharmaceuticals and consumer groups, and maintain responsibility for information technology. She will report to Gorsky.

Both McCoy and Gorsky were candidates for the position, though the company said it also considered outside candidates.

Latest News

Cooper Medical School calls its first class a competitive one

Deals and Moves: May 24

Revenue projections paint different pictures of business situation

Christie attacks revenue projections, likens OLS to Dr. Kevorkian

Award winners say development programs helped their small businesses grow

Carpet recycler relies on location to feed its growing business

After 40 years, Newark law firm is headed to suburbs


Advanced search
advanced search sponsored by:

Sign up for the NJBIZ Daily.

e-mail alert
A free summary of the day's top business stories from New Jersey delivered straight to your inbox.   Click Here
advertisement
  • Popular
  • Blogs
  • Most Commented

    1. After 40 years, Newark law firm is headed to suburbs

    2. Prudential’s landlords mount challenge to transit hub incentive

    3. Philly newspaper throwing rocks at Atlantic City

    4. J.H. Cohn merger will create nation's 11th-largest accounting firm

    5. In wake of key auction, BPU chief says more work to be done

Burn the Boats View more...

Philly newspaper throwing rocks at Atlantic City

In Focus  View more...

Celebrating small business

Intersection  View more...

Rutgers University Re-Organization: How the Camden Campus Merger with Rowan Became an Issue

Off Label View more...

G8 takes up counterfeit drugs

Waters Log View more...

Where is Grapevine?

  1. Rutgers University Re-Organization: How the Camden Campus Merger with Rowan Became an Issue (3)
  2. Concern over fracking regulations jumps in industry survey (2)
  3. Dollars and senseless on Rutgers-Rowan merger (2)
  4. At symposium, solar experts stress need for streamlined permitting (1)
  5. State revenue drops in April, missing expectations, as tax cut talk looms large (1)
advertisement
advertisement
sponsored by:

NJBIZ Poll

Tell us why:vote

advertisement

NJBIZ.com

Latest News

NJBIZ in Print

Subscribe to Print

Subscribe to E-news

Special Editions

Lists

Events

Blogs

Advertising with NJBIZ

Media Kit

Advertise in Print

Advertise in Online

Event Sponsorships

Production Info

Customer Service

Contact NJBIZ

Help & FAQ

About NJBIZ

NJBIZ Staff

Directions

Terms and Conditions

Privacy Policy

Resources

Buy Photos

Archive Search

Business Lists

Facebook

Twitter

LinkedIn



















       Email Marketing Solutions & Shopping Cart Abandonment PageTurnPro

© 2012 Journal Publications Inc. All information on this site are copyright of Journal Publications Inc. All images are the sole property of Journal Publications Inc. and no rights are granted for any use without the express written consent of Journal Publications Inc.